The Technical Analyst
Aridis Pharmaceuticals [ARDS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aridis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
9.09% $0.0669
America/New_York / 19 apr 2024 @ 14:25
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.98 mill |
| EPS: | -0.160 |
| P/E: | -0.420 |
| Earnings Date: | May 19, 2024 |
| SharesOutstanding: | 44.57 mill |
| Avg Daily Volume: | 0.104 mill |
| RATING 2024-04-19 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.420 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.420 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0609 - 0.0729 ( +/- 8.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-18 | Hamilton John F | Buy | 15 000 | Stock Options |
| 2023-09-18 | Windham-bannister Susan Richards | Buy | 15 000 | Stock Options |
| 2023-09-18 | Patzer Eric | Buy | 15 000 | Stock Options |
| 2023-09-18 | Truong Vu | Buy | 30 000 | Stock Options |
| 2023-09-18 | Jafri Hasan | Buy | 20 000 | Stock Options |
| INSIDER POWER |
|---|
| 79.56 |
| Last 96 transactions |
| Buy: 1 744 135 | Sell: 1 215 301 |
Forecast:
16:00 - $0.0669
Live Trading Signals (every 1 min)
Forecast
1: 14:35 - $0.0620
Forecast 2: 15:25 - $0.0600
Forecast 3: 16:00 - $0.0669
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0669 (9.09% ) |
| Volume | 0.0623 mill |
| Avg. Vol. | 0.104 mill |
| % of Avg. Vol | 59.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARDS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Latest Press Releases
2023-12-15 16:15:00 - Press Release
Aridis Pharmaceuticals Announces Adjournment Of Annual Meeting Of Stockholders Until January 12, 2024
Los gatos, calif., dec. 15, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (otc qb: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that its 2023 annual meeting of stockholders ("annual meeting"), scheduled for friday, december 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum. the annual meeting has been adjourned to 9:00 am local time on january 12, 2024 at the company's offices located at 983 university avenue, bldg. b, los gatos, ca 95032, to allow additional time for stockholders to vote on the proposals set forth in aridis's definitive proxy statement on schedule 14a, filed with the securities and exchange commission on november 3, 3023.
2023-11-03 16:15:00 - Press Release
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Received two grant awards from the national institute of allergy and infectious diseases, a division of the national institutes of health
2023-08-02 08:17:00 - Press Release
Aridis Pharmaceuticals Announces $2 Million Offering
Los gatos, calif., aug. 02, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (otc: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 shares of the company's common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share of common stock (or pre-funded warrant) and accompanying warrant. each warrant will have an exercise price per share of $0.20, will be exercisable immediately and will terminate on the five year anniversary of the date of issuance...
2023-07-17 16:05:00 - Press Release
Aridis Receives Agreement From The European Medicines Agency (ema) On The Clinical Study Design And A Single Confirmatory Phase 3 Study Of Ar-301
Los gatos, calif., july 17, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards) today announced positive feedback from the european medicines agency (ema) on the company's proposed single confirmatory phase 3 study of investigational monoclonal antibody candidate ar-301, which is being developed as an adjunctive therapy in combination with standard of care (soc) antibiotics for the treatment of pneumonia caused by gram-positive bacteria staphylococcus aureus (s. aureus) in mechanically ventilated hospitalized patients.
2023-07-12 08:00:00 - Press Release
Aridis' Ar-301 Monoclonal Antibody Is Among The First Biologics To Receive Fda's Qualified Infectious Diseases Product (qidp) Designation
Los gatos, calif., july 12, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the u.s. food and drug administration (fda) has granted qualified infectious disease product (qidp) designation under the generating antibiotic incentives now (gain) act for ar-301, a fully human igg1 monoclonal antibody (mab) currently in phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive staphylococcus aureus in critically ill hospitalized patients.
Latest News
2023-07-13 11:51:05 - Zacks Investment Research
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
2023-06-21 12:34:21 - Zacks Investment Research
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
2023-06-01 12:36:16 - Zacks Investment Research
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
2023-06-01 06:00:00 - PennyStocks
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer significant upside potential, particularly when approached with a well-informed strategy.
2023-05-31 11:16:41 - PennyStocks
5 Hot Penny Stocks To Watch With Big News This Week
Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.
2023-03-14 13:44:14 - Zacks Investment Research
Aridis (ARDS) Stock Up as Cystic Fibrosis Study Meets Goals
Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.
2022-11-21 21:04:04 - Zacks Investment Research
Aridis Pharmaceuticals (ARDS) Reports Q3 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-16 18:48:07 - Zacks Investment Research
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-07-01 11:31:17 - Zacks Investment Research
Here's Why Aridis Pharmaceuticals (ARDS) Looks Ripe for Bottom Fishing
Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2022-05-16 18:48:09 - Zacks Investment Research
Aridis Pharmaceuticals (ARDS) Reports Q1 Loss, Lags Revenue Estimates
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?